Merck showcases first-time pivotal Phase 3 results from oncology pipeline at ESMO 2026

MRK•2026-10-13

Merck said a Phase 3 trial of sac-TMT showed improved survival in endometrial cancer. The company showcased pivotal Phase 3 results from its oncology pipeline at ESMO 2026.

1. Trial results

Merck said its sac-TMT Phase 3 trial showed improved survival in endometrial cancer.

Merck showcases first-time pivotal Phase 3 results from oncology pipeline at ESMO 2026

1. Trial results

Related News

Albertsons declares $0.17 quarterly cash dividend for fiscal Q3 2026

BlackRock replaces WCAS in joint venture with Humana for senior clinics

Nasdaq Inc: Clear Street raises target price to $112 from $111

Intellia names Jing L. Marantz chief medical officer

Akamai signs Singapore solar VPPA with EDP APAC covering up to 17,000 MWh a year